Tumor necrosis factor alpha inhibitors as immunomodulatory antirejection agents after intestinal transplantation

American Journal of Transplantation

Volumn 11, Issue 5, 2011, Pages 1041-1050

  Gerlach, U A ^a   Koch, M ^a   Muller H P ^a   Veltzke Schlieker, W ^a   Neuhaus, P ^a   Pascher, A ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Monoclonal antibodies; rejection; small intestine; steroid refractory rejection; TNF alpha

Indexed keywords

BINDING PROTEIN; C REACTIVE PROTEIN; INFLIXIMAB; LLIPOPOLYSACCHARIDE BINDING PROTEIN; OKT 3; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CUTANEOUSMYCOSIS; DOPPLER ECHOGRAPHY; DRUG BLOOD LEVEL; DRUG EFFICACY; ENDOSCOPY; EPSTEIN BARR VIRUS INFECTION; FEMALE; GRAFT REJECTION; HUMAN; HUMAN TISSUE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE TRANSPLANTATION; MALE; MYCOSIS; PNEUMONIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ULCER; ULCERATIVE ILEITIS;

ACUTE-PHASE PROTEINS; ADULT; ANTIBODIES, MONOCLONAL; BODY WEIGHT; C-REACTIVE PROTEIN; CARRIER PROTEINS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INTESTINES; MALE; MEMBRANE GLYCOPROTEINS; STEROIDS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79955533725     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03497.x     Document Type: Article

References (30)

1. Grant D,. International intestine transplant registry data.; 2001.
2. McDiarmid SV, Farmer DG, Kuniyoshi JS, et al,. The correlation of intragraft cytokine expression with rejection in rat small intestine transplantation. Transplantation 1994; 58: 690-697. (Pubitemid 24317768)
3. Farmer DG, McDiarmid SV, Kuniyoshi J,. et al. (Intragraft expression of messenger RNA for interleukin-6 and TNF-alpha is a predictor of rat small intestine transplant rejection. J Surg Res 1994; 57: 138-142. (Pubitemid 24243250)
4. Mueller AR, Platz KP, Heckert C, et al,. The extracellular matrix: An early target of preservation/reperfusion injury and acute rejection after small bowel transplantation. Transplantation 1998; 65: 770-776. (Pubitemid 28160667)
5. Bradley SP, Pahari M, Elias G, et al,. Intragraft gene expression profile during acute cellular rejection in clinical small bowel transplantation: A case report. Transplant Proc 2006; 38: 1740-1741. (Pubitemid 44209347)
6. Pascher A, Klupp J,. Biologics in the treatment of transplant rejection and ischemia/reperfusion injury: New applications for TNFα-inhibitors? Bio Drugs 2005; 19: 211-231. (Pubitemid 41430157)
7. Alho HS, Maasilta PK, Harjula AL, et al,. Tumor necrosis factor-alpha in a porcine bronchial model of obliterative bronchiolitis. Transplantation 2003; 76: 516-523. (Pubitemid 37013256)
8. Aris RM, Walsh S, Chalermskulrat W, et al,. Growth factor upregulation during obliterative bronchiolitis in the mouse model. Am J Respir Crit Care Med 2002; 166: 417-422. (Pubitemid 34864437)
9. Eason JD, Wee S, Kawai T, et al,. Inhibition of the effects of the TNF in renal allograft recipients using recombinant human dimeric tumor necrosis factor receptors. Transplantation 1995; 59: 300-305.
10. Wollin M, Abele S, Bruns H, et al,. Inhibition of TNF-alpha reduces transplant arteriosclerosis in a murine aortic transplant model. Transplant Int 2009; 22: 342-349.
11. Langrehr JM, Gube K, Hammer MH, et al,. Short-term anti-CD4 plus anti-TNF-alpha receptor treatment in allogeneic small bowel transplantation results in long-term survival. Transplantation 2007; 84: 639-646. (Pubitemid 47429046)
12. Vincenti F,. New monoclonal antibodies in renal transplantation. Minerva Urol Nefrol 2003; 55: 57-66. (Pubitemid 36799018)
13. Buhaescu I, Segall L, Goldsmith D, et al,. New immunosuppressive therapies in renal transplantation: monoclonal antibodies. J Nephrol 2005; 18: 529-536. (Pubitemid 41824472)
14. Hering BJ, Kandaswamy R, Ansite JD, et al,. Single-donor, marginal dose islet transplantation in patients with type 1 diabetes. JAMA 2005; 293: 830-835. (Pubitemid 40250366)
15. Fishbein TM,. The current state of intestinal transplantation. Transplantation 2004; 78: 175-178.
16. Van Hogezand RA, Verspaget HW,. The future role of anti-tumour necrosis factor-alpha products in the treatment of Crohn's disease. Drugs 1998; 56: 299-305. (Pubitemid 28454259)
17. Plevy SE, Landers CJ, Prehn J, et al,. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997; 159: 6276-682.
18. Pache I, Rogler G, Felley C,. TNFα blockers in inflammatory bowel diseases: Practical consensus recommendations and a user's guide. Swiss Med Wkly 2009; 139: 278-287.
19. Knight DM, Trinh H, Le J, et al,. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30: 1443-1453.
20. Sands BE, Anderson FH, Bernstein CN, et al,. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-885. (Pubitemid 38252535)
21. Pascher A, Radke C, Dignass A, et al,. Successful infliximab treatment of steroid and OKT 3-refractory acute cellular rejection in two patients after intestinal transplantation. Transplantation 2003; 15; 76: 615-618. (Pubitemid 37013273)
22. Pascher A, Pratschke J, Neuhaus P, Present status and future perspectives of intestinal transplantation. Transplant Int 2008; 21: 401-414. (Pubitemid 351490175)
23. Pascher A, Klupp J, Schulz RJ, et al,. Klinische Ergebnisse der Dünndarm- und Multiviszeraltransplantation an der Berliner Charité. Dtsch Med Wschr 2005; 130: 387-392. (Pubitemid 40300040)
24. Ruiz P, Bagni A, Brown R, et al,. Histological criteria for the identification of acute cellular rejection in human small bowel allografts: Results of the pathology workshop at the VIII International Small Bowel Transplant Symposium. Transplant Proc 2004; 36: 335-337. (Pubitemid 38407186)
25. Rutgeerts P, Van Assche G, Vermeire S,. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126: 1593-1619.
26. Kobbe G, Schneider P, Rohr U, et al,. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplant 2001; 28: 47-49. (Pubitemid 32707616)
27. Fishbein TM, Matsumoto C, Gupta P, et al,. Infliximab for ileal ulceration after intestinal transplantation. IXth International Small Bowel Transplant Symposium, Brussels, 2005; Abstract 0-84.
28. Van Der Bijl AE, Breedveld FC, Antoni CE, et al,. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: Relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol 2008; 27: 1021-1028.
29. Van Vollenhoven RF,. Switching between biological agents. Clin Exp Rheumatol 2004; 22: 115-121.
30. Wolbrink GJ, Vis M, Lems WF, et al,. Development of anti-infliximab antibodies and relationship to clinical response in patients with rhaumatoid arthritis. Arthritis Rheum 2006; 54: 711-715.